Additional file 2 of Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

Additional file 2: Fig. S1. Forest plot of pooled seropositive rate difference between third and second dose in HSCT patients. Fig. S2. Forest plot of pooled seropositive rate difference between fourth and third dose in HSCT patients. Fig. S3. Forest plot of pooled seropositive rate difference between third and second dose in CAR-T cell patients. Fig. S4. Forest plot of seroconversion after the third dose in HSCT recipients by the interval between transplantation and vaccination initiation. This plot demonstrates higher seroconversion rates among patients with a median interval of more than 12 months from cell therapy to the first dose of immunization. Fig. S5. Forest plot of seroconversion after third dose in HSCT recipients by brand of the mRNA vaccine received.